There were 2,406 press releases posted in the last 24 hours and 431,938 in the last 365 days.

Nanox to Participate in the Oppenheimer’s Virtual Fall Healthcare Life Sciences & MedTech Summit

NEVE ILAN, Israel and TAIPEI, Taiwan, Sept. 18, 2020 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that Ran Poliakine, Chairman and Chief Executive Officer, will be participating in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which is being held virtually from September 21-23, 2020.

Presentation details:

Date: Tuesday, September 22, 2020
Time: 9:10am ET

Audio from the event will be webcast live and may be accessed at the following link: https://wsw.com/webcast/oppenheimer5/nax/2497527 or on the Investors section of the company’s website, www.nanox.vision. The webcasts will be archived and available for replay for a period of 90 days.

About Nanox:

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.

Investor Contacts:

Itzhak Maayan
Nanox Imaging
IR@nanox.vision

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

Media Contact:

Alona Stein
ReBlonde for Nanox
alona@reblonde.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.